Published in Clin Pharmacokinet on January 01, 2009
Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil. J Clin Pharmacol (2013) 0.93
A limited sampling schedule to estimate mycophenolic Acid area under the concentration-time curve in hematopoietic cell transplantation recipients. J Clin Pharmacol (2011) 0.86
Vancomycin monitoring in children using bayesian estimation. Ther Drug Monit (2014) 0.84
Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus. Br J Clin Pharmacol (2012) 0.82
Population pharmacokinetics of mycophenolic acid and metabolites in patients with glomerulonephritis. Ther Drug Monit (2010) 0.78
Application of back-propagation artificial neural network and curve estimation in pharmacokinetics of losartan in rabbit. Int J Clin Exp Med (2015) 0.77
Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II. Clin Pharmacokinet (2016) 0.75
Pharmacokinetic and pharmacodynamic analysis of inosine monophosphate dehydrogenase activity in hematopoietic cell transplantation recipients treated with mycophenolate mofetil. Biol Blood Marrow Transplant (2014) 0.75
Measurement of the integral refractive index and dynamic cell morphometry of living cells with digital holographic microscopy. Opt Express (2005) 2.40
Associations between cytomegalovirus infection and functional impairment and frailty in the BELFRAIL Cohort. J Am Geriatr Soc (2011) 2.38
Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet (2004) 2.38
Cell refractive index tomography by digital holographic microscopy. Opt Lett (2006) 2.19
Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis. Am J Respir Crit Care Med (2007) 2.18
Improved real-time RT-PCR method for high-throughput measurements using second derivative calculation and double correction. Biotechniques (2005) 2.13
Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care (2010) 2.11
The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics (2004) 2.06
Living specimen tomography by digital holographic microscopy: morphometry of testate amoeba. Opt Express (2006) 1.94
Protocol biopsy of the stable renal transplant: a multicenter study of methods and complication rates. Transplantation (2003) 1.79
Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. Arthritis Rheum (2010) 1.75
The European Register of Specialists in Clinical Chemistry and Laboratory Medicine: guide to the Register, version 3-2010. Clin Chem Lab Med (2010) 1.68
Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit (2009) 1.68
Effects of motive-oriented therapeutic relationship in a ten-session general psychiatric treatment of borderline personality disorder: a randomized controlled trial. Psychother Psychosom (2014) 1.64
Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology (2008) 1.62
Simultaneous cell morphometry and refractive index measurement with dual-wavelength digital holographic microscopy and dye-enhanced dispersion of perfusion medium. Opt Lett (2008) 1.53
Automated segmentation of multiple red blood cells with digital holographic microscopy. J Biomed Opt (2013) 1.47
The impact of the assay for measuring albumin on corrected ('adjusted') calcium concentrations. Nephrol Dial Transplant (2009) 1.43
Prolonged unconsciousness in a patient on automated peritoneal dialysis. Eur J Emerg Med (2006) 1.38
Incidence of C4d stain in protocol biopsies from renal allografts: results from a multicenter trial. Am J Transplant (2005) 1.37
Early cell death detection with digital holographic microscopy. PLoS One (2012) 1.35
In vivo endoscopic tissue diagnostics based on spectroscopic absorption, scattering, and phase function properties. J Biomed Opt (2003) 1.34
Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics (2011) 1.27
Noninvasive characterization of the fission yeast cell cycle by monitoring dry mass with digital holographic microscopy. J Biomed Opt (2009) 1.26
Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care (2010) 1.26
Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation (2005) 1.21
Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. Clin Pharmacokinet (2009) 1.21
Comparative study of human erythrocytes by digital holographic microscopy, confocal microscopy, and impedance volume analyzer. Cytometry A (2008) 1.20
Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos (2004) 1.15
Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice. Respir Res (2006) 1.12
CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin Pharmacol Ther (2006) 1.11
Potentiation of cyclophosphamide chemotherapy using the anti-angiogenic drug thalidomide: importance of optimal scheduling to exploit the 'normalization' window of the tumor vasculature. Cancer Lett (2006) 1.11
Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis. Am J Respir Cell Mol Biol (2009) 1.11
CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther (2004) 1.10
In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Dispos (2005) 1.08
Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients. Clin Pharmacokinet (2004) 1.05
Numerical parametric lens for shifting, magnification, and complete aberration compensation in digital holographic microscopy. J Opt Soc Am A Opt Image Sci Vis (2006) 1.04
Fluconazole distribution in rat dermis following intravenous and topical application: a microdialysis study. J Pharm Sci (2005) 1.04
Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods. Ther Drug Monit (2005) 1.04
Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost (2013) 1.02
The BELFRAIL (BFC80+) study: a population-based prospective cohort study of the very elderly in Belgium. BMC Geriatr (2010) 1.01
Basic protocol for transepithelial nasal potential difference measurements. J Cyst Fibros (2004) 1.01
Validation of an ELISA-based screening assay for the detection of amphetamine, MDMA and MDA in blood and oral fluid. Forensic Sci Int (2005) 1.01
A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil. Clin Pharmacokinet (2005) 1.01
Determination of transmembrane water fluxes in neurons elicited by glutamate ionotropic receptors and by the cotransporters KCC2 and NKCC1: a digital holographic microscopy study. J Neurosci (2011) 1.00
Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. Transplant Rev (Orlando) (2010) 1.00
Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations--twice daily Prograf and once daily Advagraf. Br J Clin Pharmacol (2011) 1.00
Automatic procedure for aberration compensation in digital holographic microscopy and applications to specimen shape compensation. Appl Opt (2006) 0.99
The EC4 European syllabus for post-graduate training in clinical chemistry and laboratory medicine: version 4--2012. Clin Chem Lab Med (2012) 0.99
Mechanisms underlying postmortem redistribution of drugs: a review. J Anal Toxicol (2003) 0.98
Fibromuscular dysplasia presenting as a renal infarction: a case report. J Med Case Rep (2010) 0.98
Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes. Drug Metab Dispos (2010) 0.98
Cell morphology and intracellular ionic homeostasis explored with a multimodal approach combining epifluorescence and digital holographic microscopy. J Biophotonics (2010) 0.97
Submicrometer tomography of cells by multiple-wavelength digital holographic microscopy in reflection. Opt Lett (2009) 0.97
Association of sirolimus adverse effects with m-TOR, p70S6K or Raptor polymorphisms in kidney transplant recipients. Pharmacogenet Genomics (2012) 0.97
Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation. Clin Pharmacokinet (2010) 0.96
Pharmacokinetic modeling and development of Bayesian estimators in kidney transplant patients receiving the tacrolimus once-daily formulation. Ther Drug Monit (2010) 0.96
Polarization microscopy by use of digital holography: application to optical-fiber birefringence measurements. Appl Opt (2005) 0.96
Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. Pharmacogenomics (2010) 0.95
Label-free second-harmonic phase imaging of biological specimen by digital holographic microscopy. Opt Lett (2010) 0.95
Spatial analysis of erythrocyte membrane fluctuations by digital holographic microscopy. Blood Cells Mol Dis (2009) 0.94
Use of Neoral C monitoring: a European consensus. Transpl Int (2005) 0.94
Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Fundam Clin Pharmacol (2002) 0.94
Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. Ther Drug Monit (2004) 0.94
A simultaneous d-optimal designed study for population pharmacokinetic analyses of mycophenolic Acid and tacrolimus early after renal transplantation. J Clin Pharmacol (2011) 0.93
Metabolism of sirolimus in the presence or absence of cyclosporine by genotyped human liver microsomes and recombinant cytochromes P450 3A4 and 3A5. Drug Metab Dispos (2006) 0.93
Pesticide contamination of workers in vineyards in France. J Expo Sci Environ Epidemiol (2006) 0.93
Total aberrations compensation in digital holographic microscopy with a reference conjugated hologram. Opt Express (2006) 0.93
Vancomycin penetration of uninfected pleural fluid exudate after continuous or intermittent infusion. Antimicrob Agents Chemother (2003) 0.93
An overview of monitoring and supplementation of omega 3 fatty acids in cystic fibrosis. Clin Biochem (2007) 0.93
Age-related changes in the protein and mRNA levels of CYP2E1 and CYP3A isoforms as well as in their hepatic activities in Wistar rats. What role for oxidative stress? Arch Toxicol (2003) 0.92
1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation. Pharmacogenet Genomics (2007) 0.92
Time of drug administration, CYP3A5 and ABCB1 genotypes, and analytical method influence tacrolimus pharmacokinetics: a population pharmacokinetic study. Ther Drug Monit (2009) 0.91
Screening of drugs and toxic compounds with liquid chromatography-linear ion trap tandem mass spectrometry. Clin Chem (2006) 0.91
C-terminal FGF23 is a strong predictor of survival in systolic heart failure. Peptides (2012) 0.90
Comparison of liquid chromatography-tandem mass spectrometry with a commercial enzyme-multiplied immunoassay for the determination of plasma MPA in renal transplant recipients and consequences for therapeutic drug monitoring. Ther Drug Monit (2004) 0.90
Iodine and iron status of pregnant women in Lubumbashi, Democratic Republic of Congo. Public Health Nutr (2013) 0.90
Pharmacokinetic modelling and development of Bayesian estimators for therapeutic drug monitoring of mycophenolate mofetil in reduced-intensity haematopoietic stem cell transplantation. Clin Pharmacokinet (2009) 0.90
CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation. Pharmacogenomics (2010) 0.90
Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients. Pharmacogenet Genomics (2007) 0.90
Real-time dual-wavelength digital holographic microscopy with a single hologram acquisition. Opt Express (2007) 0.90
Hyperhomocysteinemia and venous thromboembolism: a risk factor more prevalent in the elderly and in idiopathic cases. Thromb Res (2002) 0.90
Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy. Int J Antimicrob Agents (2011) 0.89
Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies. Clin Pharmacokinet (2008) 0.89
Glycosomal ABC transporters of Trypanosoma brucei: characterisation of their expression, topology and substrate specificity. Int J Parasitol (2010) 0.89
Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients. Clin Pharmacokinet (2006) 0.89
Long-term renal function after HELLP syndrome. Gynecol Obstet Invest (2003) 0.88
A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients. Br J Clin Pharmacol (2006) 0.88
The glomerular filtration rate estimated by new and old equations as a predictor of important outcomes in elderly patients. BMC Med (2014) 0.88
The future of hospital laboratories. Position statement from the Royal Belgian Society of Clinical Chemistry (RBSCC). Clin Chem Lab Med (2009) 0.88